07:00 , Oct 16, 2006 |  BC Week In Review  |  Clinical News

Saforis regulatory update

MOGN received an approvable letter from FDA for Saforis oral suspension to treat and prevent oral mucositis in which the agency asked for an additional Phase III trial. MOGN gained the oral formulation of glutamine...
07:00 , Oct 16, 2006 |  BioCentury  |  Finance

Ebb & Flow

Like many top tier biotechs,...
00:47 , Oct 13, 2006 |  BC Extra  |  Company News

FDA wants another Saforis trial

MGI Pharma (MOGN) said it received an approvable letter from FDA for Saforis oral suspension to treat and prevent oral mucositis in which the agency asked for an additional Phase III trial. MOGN said it...
01:18 , Jun 13, 2006 |  BC Extra  |  Company News

Saforis gets Priority Review

FDA accepted for filing and granted Priority Review to an NDA from MGI Pharma (MOGN) for Saforis oral suspension to treat and prevent oral mucositis in patients receiving mucotoxic cancer therapy. The PDUFA date is...
07:00 , Oct 18, 2004 |  BioCentury  |  Finance

EPS watch

EPS watch...
07:00 , Oct 13, 2004 |  BC Extra  |  Financial News

MGI reports earnings

MOGN reported third quarter revenue of $55.5 million, up from $21.2 million in the same period in 2003. Sales of Aloxi palonosetron to prevent chemotherapy-induced nausea and vomiting were $47.6 million, up from $4.9 million...
07:00 , Sep 13, 2004 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
07:00 , Sep 6, 2004 |  BC Week In Review  |  Company News

Aesgen, MGI, Zycos deal

Aesgen shareholders are eligible for $58 million in regulatory and sales milestones, plus and a 5% royalty. MOGN plans to start a second Phase III trial of Saforis early next year. Also in early 2005,...
07:00 , Sep 6, 2004 |  BioCentury  |  Finance

Ebb & Flow

After a busy summer,...
07:00 , Sep 6, 2004 |  BioCentury  |  Strategy

Asset accumulation

A few months ago, BioCentury spilled a lot of ink to deconstruct the NRDO model of no-research, development only companies being formed to scavenge for products or technologies that can be commercialized quickly and offer...